Nevi and pregnancy

Innovative applications of acellular adipose matrix derived film in skin soft tissue expansion

BACKGROUND

Skin dilation generates "extra" skin tissue through mechanical traction, but its effectiveness is limited by the proliferation capacity of keratinocytes, fibroblasts and the level of angiogenesis. Cutaneous application of drug and subcutaneous injection are common interventions to promote skin dilation, but they have defects such as uneven drug distribution, high risk of infection and single targeting. Although Acellular adipose matrix (AAM) has the potential to promote cell proliferation and angiogenesis, its hydrogel/powder dosage forms still need frequent injection, which limits clinical application.

RESULTS

In this study, Acellular adipose matrix derived film (AAF) was successfully developed, and a flexible film was formed by acellular - lyophilized - enzymolysis - self-assembly process. In vitro experiments confirmed that AAF significantly promoted the activity of Human Immortalized Epidermal Cells (HaCaTs), Normal Skin Fibroblasts (NFbs) and Human Umbilical Endothelial Cells (HUVECs); It was also found that AAF can induce adipose mesenchymal stem cells (ASCs) to differentiate into adipocytes and promote subcutaneous fat regeneration. In vivo, the rat model showed that AAF wrapping expander could effectively improve the skin expansion efficiency, promote the skin thickness increase in the expanded area, and the density of new blood vessels was significantly increased compared with the comparative group, and there was no complication such as infection or skin collapse. It was found for the first time that AAF successfully formed new adipose tissue in the subcutaneous area.

CONCLUSION

AAF innovatively integrates the bionic structure of extracellular matrix and slow-release function, and solves the uneven drug distribution and associated infection risk of traditional intervention methods by regulating the synergistic regeneration of epidermodermis and vascular units. Its mechanical adaptability (dry toughness/wet plasticity) and the ability of inducing adipose regeneration provide a new strategy of both structural strengthening and metabolic support for skin dilation, also laying a mechanism and empirical foundation for clinical transformation of tissue engineering materials.

Changes in Melanocytic Nevi and Melanoma Associated With Pregnancy: A Scoping Review

Pregnancy is a transformative period characterized by numerous physiological and hormonal changes, including those affecting the skin. Among these changes, alterations in melanocytic nevi and the potential risk of melanoma are areas of significant interest and ambiguity. This scoping review aims to synthesize existing literature on these topics to provide a comprehensive understanding and identify gaps in knowledge. Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping Reviews guidelines, a systematic search was conducted; out of 4824 identified articles, 80 met the inclusion criteria. While some studies suggest hormonal influences might accelerate melanocyte growth, others argue that perceived growth is due to mechanical stretching of the skin, and still others found no significant size changes. Pigmentary changes in nevi are more consistently reported, though some researchers advocate viewing them with suspicion until proven benign. The risk of developing pregnancy-associated melanoma is contentious, with some studies proposing that hormonal changes and gestational immunosuppression increase susceptibility, but the evidence remains inconclusive. Prognostic outcomes are equally disputed, with conflicting findings on pregnancy-associated melanoma thickness, recurrence rates, and survival outcomes. We also performed a novel semi-quantitative analysis to assess attitudes on the risk and prognosis of pregnancy-associated melanoma in the literature, demonstrating that authors of narrative reviews are more likely to oppose theories of pregnancy as a trigger for melanoma development or progression than researchers who conducted the primary investigations. These inconsistencies in the literature highlight the need for further research with standardized methodologies and consideration of confounding factors.

Melanoma in pregnancy

Cutaneous melanoma is a malignant neoplasm of melanocytes that most frequently affects the skin. It is the most common malignancy in women of childbearing age, and accounts for almost one-third of all malignancies diagnosed during gestation. The pathophysiology of melanoma, particularly during pregnancy, is not well understood, but there are several ways in which the physiologic state pregnancy may impact melanoma. Based on the available literature, pregnancy does not seem to worsen maternal outcomes with melanoma, and outside of placental and fetal metastases, melanoma does not seem to cause serious obstetric or fetal complications. Treatment of localized melanoma during pregnancy follows guidelines for the general population, but advanced melanoma in pregnancy poses unique challenges given the lack of unifying research and management recommendations. Herein, we review the current literature, highlighting diagnostic clinical pearls and key multidisciplinary management considerations with regard to melanoma in the child-bearing population.

AI-assisted Total Body Dermoscopic Evaluation of Changes in Melanocytic Nevi during Pregnancy: A Prospective, Comparative Study of 2,799 Nevi

Pregnancy-associated changes in melanocytic nevi (MN), apart from size increase on the trunk, remain a topic of debate. We conducted the first prospective study to investigate dermoscopic changes in MN comparing pregnant with non-pregnant women on all body parts using a market-approved convolutional neural network (CNN). We included 25 pregnant and 25 non-pregnant women from Basel, Switzerland, who underwent standard skin cancer screenings and whose MN > 2 mm were digitally recorded and analysed by a CNN. Pregnant women were examined three times: in the first and third trimester and 8-12 weeks postpartum; non-pregnant women twice in an interval of 17-21 weeks. We analysed 2,799 MN. In pregnant women, diameter[p < 0.001], area[p < 0.001], number of colours [p = 0.009], shape asymmetry[p = 0.005] and border sharpness[p = 0.006] (inversely proportional value) increased while ellipseness [p < 0.001] decreased from first trimester to postpartum. Changes occurred mainly during the third trimester to postpartum. Compared to non-pregnant women (only first to third trimester) MN on the upper extremities of pregnant women increased in area[p = 0.011] and diameter[p = 0.025] and decreased in ellipseness[p = 0.037]. MN on the lower extremities increased in area[p = 0.044] and MN on the back increased in colour asymmetry[p = 0.022].

Melanoma and melanocytic nevi in pregnancy

A changing melanocytic nevus during pregnancy should be biopsied promptly. For women with the dysplastic nevus syndrome, there may be more changes in nevi during pregnancy, requiring close monitoring. Melanoma is one of the most common malignancies that occurs during pregnancy. Those diagnosed with a localized melanoma before, during, or after pregnancy do not have an altered prognosis; however, a few studies have noted thicker melanomas and poorer prognosis when melanoma is diagnosed in the first year postpartum, possibly due to a delay in diagnosis. Although local excision of melanomas can be performed safely during pregnancy, sentinel lymph node biopsy during pregnancy is controversial for the timing and method. There are safe methods of imaging with some special precautions for staging in pregnant women. Systemic therapy requires an interdisciplinary team to assist in patient decision-making because some of these agents are teratogenic. There is no reason to withhold combined estrogen-progestin oral contraceptives or menopausal hormone therapy in those with a previous diagnosis of melanoma, nor should future pregnancies be delayed in those diagnosed with localized melanoma. Only limited data are available concerning prognosis for women with a melanoma diagnosis after in vitro fertilization.

["Red flags" during pregnancy-skin symptoms and their causes during pregnancy]

Pregnancy is a special state for the expectant mother. Not only is a human being growing, but the pregnant woman's body is also constantly changing during the 40-week pregnancy. One organ that is frequently affected by these changes is the skin. As diagnosis and treatment during pregnancy can present treating physicians with particular challenges, it is important to know the relevant pregnancy dermatoses, to recognize and diagnose them reliably, and to observe red flags in order to protect the pregnant women and the unborn child. In this article, the most important changes in the skin of pregnant patients are explained and potential warning signs are presented. In addition to aspects of altered pigmentation, the influence of pregnancy on pre-existing inflammatory dermatoses and their improvement or worsening is also described. The occurrence of so-called specific pregnancy dermatoses over the course of pregnancy is also explained. Finally, the extent to which autoimmune diseases of the mother can also affect the unborn child and to what extent skin changes in the newborn can indicate a disease of the mother are described. The respective "red flags" are presented as leading symptoms and their relevance is discussed.

Updates on the dermatopathology of pregnancy-associated skin conditions

Pathologists provide valuable input in the dermatological care of pregnant patients in various contexts. This article provides dermatopathology updates on cutaneous changes associated with pregnancy, organized based on the following classification system: physiological skin changes in pregnancy, specific dermatoses of pregnancy, dermatoses modified in pregnancy, and skin neoplasms in pregnancy. Awareness of the impact of pregnancy on the skin by pathologists is important, as this is an opportunity to contribute to diagnostic precision in this patient population.

The effect of menopausal hormone therapy on the risk of melanoma and keratinocyte skin cancer: A systematic review and meta-analysis of observational studies

BACKGROUND

Whether menopausal hormone therapy (MHT) increases the risk of skin cancer is controversial.

AIM

To systematically review and meta-analyze evidence regarding the association of MHT with the risk of melanoma and keratinocyte cancer (KC).

MATERIAL AND METHODS

A comprehensive literature search was conducted of the PubMed, Scopus and Cochrane databases, through to 30 October 2021. Skin neoplasms were divided into melanoma and KC. In the latter category, both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) were considered. The results are presented as hazard ratios (HR) with 95 % confidence intervals (CI). The I² index was used to assess heterogeneity. Subgroup analysis and sensitivity analysis were also conducted in order to explore potential differences among studies.

RESULTS

Twenty-seven studies were included in the qualitative and 23 in the quantitative analysis, with a total of 2,612,712 menopausal women (25,126 with skin cancer; 20,150 with melanoma). MHT was associated with an increased risk of melanoma (HR 1.11; 95 % CI 1.05-1.19; I² 45%). With regard to MHT type, both estrogen monotherapy (HR 1.22, 95 % CI 1.16-1.29; I² 0%) and estrogen in combination with progestogen (HR 1.11, 95 % CI 1.05-1.18, I² 26%) significantly increased that risk. Regarding melanoma subtype, superficial spreading melanoma (SSM) and lentigo maligna melanoma (LMM) were the only histologic subtypes associated with MHT use. MHT was also associated with an increased risk of KC (HR 1.17, 95 % CI 1.04-1.31, I² 83%), specifically BCC (HR 1.22, 95 % CI 1.12-1.32; I² 29%). Longer duration (>5 years) of MHT, current use and estrogen monotherapy were associated with an increased KC risk compared with no use.

CONCLUSION

The use of MHT by postmenopausal women was associated with an increased risk of melanoma and KC. This risk was higher for current MHT users and those treated for over 5 years.

Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease

Approximately one-third of women diagnosed with melanoma are of child-bearing age. The annual incidence of melanoma has risen steadily over the last 40 years, resulting in increasing numbers of women diagnosed with melanoma both during pregnancy, and post-partum. To date, there are no formal guidelines on the management of pregnancy associated melanoma (PAM), both early stage and metastatic. This article reviews the existing literature and provides a framework for the investigation and multidisciplinary management of PAM.

Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide

BACKGROUND

Afamelanotide (AFA) is a synthetic analogue of α-melanocyte-stimulating hormone that is approved for the treatment of patients affected by erythropoietic protoporphyria (EPP). AFA induces a "sun free" tanning and changes of acquired melanocytic nevi (AMN) that are generically described as "darkening".

OBJECTIVES

To assess clinical and dermoscopic AMN changes during AFA treatment.

METHODS

Adult EPP patients treated with two AFA implants 50 days apart were enrolled. They underwent a clinical and dermoscopic examination of all AMN at baseline (T0), and after 5 (T1) and 12 (T2) months from the first AFA implant. The general pattern, symmetry, number, and size of pigmented globules, morphology of the pigment network, and dermoscopic melanoma features were assessed.

RESULTS

Fifteen patients were enrolled with 103 AMN. At T1 all reticular and 2-component AMN showed a focal network thickening that returned to baseline by T2. The increase of globules' number was observed at T1 but not at T2. The difference in number was not influenced by patients' age or phototype. Dermoscopic changes suggestive of malignancy were never seen. The development of new AMN was never registered.

CONCLUSIONS

AFA treatment induces reversible changes of AMN dermoscopic morphology without findings suggestive of malignant transformation and it does not stimulate the development of new AMN.

Physiological changes of the skin during pregnancy

The appearance of skin changes during pregnancy is inevitable and physiologically determined. This period is characterized by hormonal, immunological and metabolic changes and associated physiological changes in the skin. These include pigmentation (linea nigra, melasma, pseudoacanthosis, growth and appearance of pigmented nevi), changes in connective tissue (striae distensae, skin tags), blood vessels (stellate hemangiomas, erythema of the palms, vasodilatation, edema, cutis marmorata) and skin appendages (increased sebaceous and eccrine glands activity, reduced hair loss and increased hair density, onychodystrophy). It is important to inform women about possible changes, to recognize them in time to reduce the impact of their appearance on the health and course of pregnancy, as well as to avoid unnecessary tests and interventions.

Melanoma in pregnancy: certainties unborn

Melanoma diagnosed during childbearing period or up to 1 year after delivery is defined as pregnancy-associated melanoma (PAM). There is some evidence that PAM has worse prognosis if compared with melanoma in nonpregnant women, although literature is still inconclusive. Many biological mechanisms could explain this behavior, such as hormonal and immune status, increased lymphangiogenesis but also delay in diagnostic and therapeutic management. If PAM is suspected, a prompt excisional biopsy under local anesthesia can be performed regardless of the gestational period. Conversely, additional staging procedures (such as sentinel lymph node biopsy or imaging) and systemic therapy are still debatable during pregnancy. A multidisciplinary tailored approach should be preferred, together with exhaustive counseling of the mother.

Cutaneous Surgery in Patients Who Are Pregnant or Breastfeeding

Dermatologic surgery in pregnant/postpartum patients requires deliberate consideration. Although surgery can be safely performed during any trimester, the second trimester and immediate postpartum period is optimal. Surgery should not be delayed for melanoma/high-risk skin cancers. Perioperative positioning, analgesic, antiseptic, and antibiotic selection should be deliberate to avoid risk to the patient/fetus/infant. The left lateral tilt position reduces aortocaval compression syndrome. Lidocaine and epinephrine can be used safely. Alcohol and chlorhexidine are considered safe. Antibiotics commonly used in skin surgery are safe in pregnancy and lactation. Acetaminophen is first line for pain management. Nonsteroidal antiinflammatory drugs should be avoided.

Guidelines of care for the management of primary cutaneous melanoma

The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Dermatology clinical practice guideline, updated treatment recommendations are provided for patients with primary cutaneous melanoma (American Joint Committee on Cancer stages 0-IIC and pathologic stage III by virtue of a positive sentinel lymph node biopsy). Biopsy techniques for a lesion that is clinically suggestive of melanoma are reviewed, as are recommendations for the histopathologic interpretation of cutaneous melanoma. The use of laboratory, molecular, and imaging tests is examined in the initial work-up of patients with newly diagnosed melanoma and for follow-up of asymptomatic patients. With regard to treatment of primary cutaneous melanoma, recommendations for surgical margins and the concepts of staged excision (including Mohs micrographic surgery) and nonsurgical treatments for melanoma in situ, lentigo maligna type (including topical imiquimod and radiation therapy), are updated. The role of sentinel lymph node biopsy as a staging technique for cutaneous melanoma is described, with recommendations for its use in clinical practice. Finally, current data regarding pregnancy and melanoma, genetic testing for familial melanoma, and management of dermatologic toxicities related to novel targeted agents and immunotherapies for patients with advanced disease are summarized.

Pregnancy and Melanoma: Recommendations for Clinical Scenarios

Managing pregnant patients with a history of melanoma or with a melanoma diagnosis can be daunting and confusing for dermatologists. We present three clinical scenarios that raise questions about the safety of pregnancy in patients with a history of melanoma, skin biopsies during pregnancy, and excisions and sentinel lymph node biopsies during pregnancy. Our recommendations incorporate the most up-to-date clinical data to help guide clinicians when faced with pigmented lesions and melanoma in a pregnant patient.

Physiologic changes of pregnancy: A review of the literature

Throughout pregnancy, the body undergoes a variety of physiologic changes. The cutaneous findings can be most noticeable and often worrisome to both physicians and patients. Obstetricians and dermatologists must be able to differentiate between changes that are benign and those that may be pathologic. Most physicians recognize benign changes that are commonly described in literature such as hyperpigmentation, melasma, striae gravidarum, and telogen effluvium; however, they may be unaware of changes that tend to be less frequently discussed. This comprehensive review provides a broad overview of the physiologic cutaneous changes that occur during pregnancy as described in the literature over the past 10 years.